<DOC>
	<DOCNO>NCT00020332</DOCNO>
	<brief_summary>RATIONALE : Drugs use chemotherapy use different way stop tumor cell divide stop grow die . Combining one drug may kill tumor cell . PURPOSE : Phase I/II trial study effectiveness combination chemotherapy treat patient locally advance metastatic breast cancer .</brief_summary>
	<brief_title>Docetaxel Flavopiridol Treating Patients With Locally Advanced Metastatic Breast Cancer</brief_title>
	<detailed_description>OBJECTIVES : - Determine maximum tolerate dose docetaxel flavopiridol patient previously treat locally advanced metastatic breast cancer . - Determine dose-limiting toxicity , toxicity profile , pharmacokinetics regimen patient . - Determine activity regimen patient . - Determine objective response rate patient treat regimen . - Determine immune dysfunction produce regimen measure lymphocyte subpopulation , include T-cell activation/memory subset natural killer cell/lymphokine-activated killer cell functional subset patient . - Determine ability positron emission tomography scan predict response patient treat regimen . - Determine response duration , time treatment failure , overall survival patient treat regimen . - Determine quality life patient treat regimen . - Determine whether regimen associate development prothrombotic state patient . OUTLINE : This dose-escalation study . Patients receive docetaxel IV 1 hour day 1 follow flavopiridol IV 1 hour IV continuously day 2-4 . Treatment repeat every 3 week absence disease progression unacceptable toxicity . Sequential dose escalation docetaxel precede follow sequential dose escalation flavopiridol . Cohorts 3-6 patient receive escalate dos docetaxel precede follow escalate dos flavopiridol maximum tolerate dose ( MTD ) combination determine . The MTD define dose precede 2 6 patient experience dose-limiting toxicity . Once MTD determine , 22 additional patient accrue receive flavopiridol docetaxel recommend phase II dose . Quality life assess baseline , every 3 course study , completion study . PROJECTED ACCRUAL : A total 49 patient ( 27 phase I 22 phase II ) accrue study within 2 year .</detailed_description>
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Docetaxel</mesh_term>
	<mesh_term>Alvocidib</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically confirm stage III IV adenocarcinoma breast Phase I : Evaluable disease allow Phase II : At least 1 site measurable disease No bone metastasis site disease No carcinomatous meningitis brain metastases Hormone receptor status : Not specify PATIENT CHARACTERISTICS : Age : 18 Sex : Male female Menopausal status : Not specify Performance status : ECOG 02 Life expectancy : Not specify Hematopoietic : Granulocyte count least 1,500/mm^3 Platelet count least 100,000/mm^3 No active coagulopathy require therapeutic anticoagulation Hepatic : Bilirubin great upper limit normal ( ULN ) SGOT great 1.5 time ULN Alkaline phosphatase great 2.5 time ULN No Gilbert 's disease Renal : Creatinine great 1.5 mg/dL Cardiovascular : Left ventricular ejection fraction least 50 % without clinical sign symptom heart failure No uncontrolled hypertension ( sustain systolic blood pressure ( BP ) great 180 mm Hg diastolic BP great 100 mm Hg ) No uncontrolled cardiac arrhythmia No myocardial infarction within past year No significant ischemia valvular heart disease Other : Not pregnant nursing Negative pregnancy test Fertile patient must use effective contraception No medical psychiatric condition would increase risk No malignancy within past 5 year except carcinoma situ cervix nonmelanomatous skin cancer No grade 2 great peripheral neuropathy No diabetes mellitus fasting blood sugar great 200 mg/dL No active unresolved infection No serious concurrent medical illness No history hypersensitivity reaction product contain polysorbate 80 ( Tween 80 ) PRIOR CONCURRENT THERAPY : Biologic therapy : Not specify Chemotherapy : No prior flavopiridol Prior adjuvant chemotherapy advance disease allow within 6 month diagnosis metastatic disease At least 4 week since prior chemotherapy ( 6 week nitrosourea 8 week UCN01 ) recover Phase I : Any number prior chemotherapy regimens metastatic carcinoma breast allow Phase II : No 2 prior chemotherapy regimens metastatic carcinoma breast Endocrine therapy : Prior hormonal therapy metastatic adjuvant setting allow At least 2 week since prior hormonal therapy evidence disease improvement radiography therapy Concurrent corticosteroid allow study premedication hypersensitivity reactions/adverse event Radiotherapy : No concurrent radiotherapy Surgery : Not specify Other : No concurrent antineoplastic therapy No concurrent investigational drug</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2002</verification_date>
	<keyword>stage IV breast cancer</keyword>
	<keyword>stage IIIA breast cancer</keyword>
	<keyword>recurrent breast cancer</keyword>
	<keyword>stage IIIB breast cancer</keyword>
	<keyword>male breast cancer</keyword>
</DOC>